Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 23

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 23
---
Sight Psychotropic Mental Health Medication TestWe hold a license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions relating to GeneSight testing.Certain patents began expiring in 2024 and the remaining pending and issued patents have terms expected to begin expiring in 2027.Claims relating to biomarkers, systems and methods for detecting single nucleotide polymorphisms and selecting and/or optimizing therapy based on such detection.Foresight Carrier ScreenWe own one or more issued patents and pending patent applications in the U.S. and other jurisdictions that relate to laboratory and informatic methods used to enhance Foresight testing.These pending and issued patents have terms expected to begin expiring in 2032.Claims relating to systems and methods for detecting genetic sequences.Prequel Prenatal ScreenWe own or hold a license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions that relate to laboratory and informatic methods used to enhance Prequel testing.These pending and issued patents have terms expected to begin expiring in 2032.Claims relating to systems and methods for detecting genetic sequences.MRDWe own one or more issued patents and pending patent applications in the U.S. or other jurisdictions relating to MRD testing.These pending and issued patents have terms expected to begin expiring in 2037.Claims relating to systems and methods for preparing enriched DNA fractions, detecting circulating tumor DNA, and identifying tumor variants.SneakPeekWe own one or more issued patents and pending patent applications in the U.S. or other jurisdictions relating to SneakPeek testing.These pending and issued patents have terms expected to begin expiring in 2040.Claims relating to methods of improving the accuracy of fetal sex determination by reducing a level of contaminating DNA in a blood sample from a pregnant human subject and/or methods of detecting target fetal nucleic acids in a sample.

We have or intend to seek patent protection in the United States and major foreign jurisdictions for these and other inventions which we believe are patentable and where we believe our interests would be best served by seeking patent protection. 

13

Table of Contents

However, any patents issued to us or our licensors may not afford meaningful protection for our products or technology or may be subsequently circumvented, invalidated or narrowed or found unenforceable. Any patent applications which we have filed, or will file, or to which we have licensed or will license rights may not issue, and patents that do issue may not contain commercially valuable claims. In addition,